STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $7,917,309.21 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 497,631 shares of STAAR Surgical stock in a transaction that occurred on Friday, April 4th. The shares were purchased at an average cost of $15.91 per share, with a total value of $7,917,309.21. Following the transaction, the insider now directly owns 13,194,210 shares of the company’s stock, valued at $209,919,881.10. This represents a 3.92 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 7th, Broadwood Partners, L.P. acquired 138,054 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.61 per share, with a total value of $2,155,022.94.
• On Wednesday, April 2nd, Broadwood Partners, L.P. acquired 31,780 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.43 per share, for a total transaction of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.46 per share, for a total transaction of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was bought at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The stock was bought at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was acquired at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The shares were acquired at an average cost of $15.49 per share, with a total value of $565,880.68.

STAAR Surgical Price Performance

Shares of STAA opened at $15.87 on Thursday. The firm has a 50 day simple moving average of $17.94 and a 200-day simple moving average of $24.22. The stock has a market cap of $782.79 million, a price-to-earnings ratio of -38.71 and a beta of 0.75. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $51.81.

Wall Street Analyst Weigh In

STAA has been the topic of a number of recent analyst reports. BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. StockNews.com cut STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Stephens reiterated an “equal weight” rating and issued a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday, March 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and an average price target of $25.29.

Institutional Investors Weigh In On STAAR Surgical

Several hedge funds have recently modified their holdings of the company. Resona Asset Management Co. Ltd. acquired a new stake in STAAR Surgical in the 4th quarter worth about $36,411,000. Vanguard Group Inc. raised its holdings in shares of STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after buying an additional 319,441 shares during the period. Yunqi Capital Ltd lifted its position in STAAR Surgical by 48.9% during the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock worth $18,640,000 after acquiring an additional 252,113 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after buying an additional 172,779 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in STAAR Surgical by 25.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock worth $20,728,000 after purchasing an additional 171,046 shares during the last quarter. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.